The US Anatomic Pathology Market is increasingly defined by molecular pathology integration, where traditional morphologic diagnosis is supplemented by genomic, transcriptomic, and proteomic analysis to guide precision oncology treatment selection. Anatomic pathologists now routinely perform biomarker testing on tissue specimens to identify mutations, expression patterns, and immune profiles that determine targeted therapy and immunotherapy eligibility. The US Anatomic Pathology Market is projected to grow through 2030, driven by companion diagnostic expansion, next-generation sequencing panel adoption, liquid biopsy correlation with tissue findings, multiplex immunohistochemistry advances, and standardization of biomarker reporting across cancer types.

The US Anatomic Pathology Market continues evolving with significant industry developments across the US Anatomic Pathology Market, where PD-L1 immunohistochemistry guides immunotherapy decisions. Next-generation sequencing panels detecting actionable mutations. HER2 testing determining trastuzumab eligibility in breast and gastric cancer. MSI and TMB assessment for checkpoint inhibitor response. EGFR and ALK testing in lung adenocarcinoma. BRAF mutation analysis in melanoma. Companion diagnostic development aligned with drug approvals. Comprehensive molecular diagnostic landscape.

Precision oncology expansion requiring biomarker testing on every cancer. Tumor-agnostic approvals expanding testing indications. Turnaround time pressure for treatment-naive specimens. Reimbursement challenges for comprehensive profiling.

RNA sequencing revealing fusion events missed by DNA panels. Spatial transcriptomics mapping gene expression in tissue context. Multiplex immunofluorescence profiling immune microenvironments. Artificial intelligence predicting biomarker status from morphology. Organoid models testing drug sensitivity on patient tissue. Standardized biomarker reporting through CAP guidelines. Point-of-care molecular testing in resource-limited settings. Advanced precision pathology approach.

The US Anatomic Pathology Market will likely expand through 2030 substantially. RNA sequencing will likely become standard for fusion detection. Spatial transcriptomics will likely reveal treatment resistance mechanisms. Multiplex imaging will likely profile entire immune landscapes. AI morphology prediction will likely triage biomarker testing. Organoid drug testing will likely personalize treatment selection. Standardization will likely improve inter-laboratory concordance. Market elevation will likely deepen.

US anatomic pathology substantially benefits from molecular integration, precision oncology demand, and biomarker standardization, elevating tissue diagnosis from descriptive to predictive and personalized. Continued spatial and RNA-based innovation will likely perfect precision pathology capabilities.

A: PD-L1 immunohistochemistry guides immunotherapy eligibility across multiple cancers. HER2 testing determines trastuzumab eligibility in breast and gastric cancer. EGFR and ALK testing identifies targeted therapy options in lung adenocarcinoma. BRAF mutation analysis guides melanoma treatment selection. MSI and TMB assessment predicts checkpoint inhibitor response. Next-generation sequencing panels detect actionable mutations across tumor types. Comprehensive biomarker testing. PD-L1. HER2. NGS.

A: Companion diagnostics align biomarker testing with specific drug approvals ensuring appropriate patient selection. RNA sequencing reveals fusion oncogenes missed by DNA-only panels. Spatial transcriptomics maps gene expression within tissue architecture revealing resistance mechanisms. Multiplex immunofluorescence profiles immune microenvironments predicting immunotherapy response. Organoid models test drug sensitivity on living patient tissue. AI predicts biomarker status from morphology alone triaging testing. Comprehensive precision advances. Companion diagnostics. RNA-seq. Spatial transcriptomics.